Search | TVST | ARVO Journals

Showing 1 – 20 of 34

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Genetics July 2024

ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2

PDF

Robyn H. Guymer; Rufino Silva; Mercedeh Ghadessi; Sergio Leal; Isabella Gashaw; Amy Damask; Charles Paulding; Kay D. Rittenhouse
TAGS: anti-vascular endothelial growth factor therapy, exudative age-related macular degeneration, genetics, genome-wide association study, pharmacogenetics, surrogate endpoints, single nucleotide polymorphism, candidate disease gene
Invest. Ophthalmol. Vis. Sci.. 2024; 65(8):17. https://doi.org/10.1167/iovs.65.8.17

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

Associations between structural phenotype and pathway-specific polygenic risk scores in intermediate age-related macular degeneration – a MACUSTAR report

Lukas Schloesser; Jan Henrik Terheyden; Charlotte Behning; Hannah Klinkhammer; Davide Garzone; Marlene Sassmannshausen; Steffen Schmitz-Valckenberg; Carel C B Hoyng; Clarisa Sanchez; Ulrich F O Luhmann; Klaus-Peter Moll; Sergio Leal; Matthias Schmid; Frank G Holz; Robert Finger

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):378.

ARVO Annual Meeting Abstract June 2024

Comparable efficacy with aflibercept 8 mg at extended dosing intervals beyond q16 versus 2 mg q8 in Asian patients with nAMD in PULSAR through Week 96

Xiaodong Sun; Shih-Jen Chen; xin Zhang; Andrea Schulze; Tobias Machewitz; Min Zhao; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):220.

ARVO Annual Meeting Abstract June 2024

Aflibercept 8 mg monotherapy shows maintained efficacy over 96 weeks, with the ability to extend dosing intervals beyond every 16 weeks, in patients with PCV in the PULSAR Phase 3 trial

Rufino Silva; Tien Y Wong; Gemmy Cheung; Jeffrey S Heier; Won Ki Lee; Tomohiro Iida; xin Zhang; Tobias Machewitz; Andrea Schulze; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):219.

ARVO Annual Meeting Abstract June 2024

Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg

Andreas Stahl; Eric Schneider; Ursula Maria Schmidt-Ott; Claudia Tueckmantel; Andrea Schulze; Alyson J Berliner; Karen W Chu; Robert Vitti; Kimberly Reed; xin Zhang; Peter Morgan-Warren; Rohini Rao; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):217.

ARVO Annual Meeting Abstract June 2024

The prognostic power of baseline visual function deficits in intermediate age-related macular degeneration (iAMD) for progression to late AMD - A MACUSTAR study report

Hannah M P Dunbar; Charlotte Behning; Alison M Binns; Jan Henrik Terheyden; Stephen H Poor; Robert Finger; David P. Crabb; Sergio Leal; Adnan Tufail; Frank G Holz; Matthias Schmid; Ulrich F O Luhmann

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1485.

ARVO Annual Meeting Abstract June 2024

Association of Ellipsoid Zone Reflectivity and Choriocapillaris Flow in Age-Related Macular Degeneration: a MACUSTAR study report

Yannick N. Liermann; Ben Isselmann; Marlene Sassmannshausen; Sandrine H. Künzel; Ulrich F O Luhmann; Sergio Leal; Matthias Schmid; Robert Finger; Steffen Schmitz-Valckenberg; Frank G Holz; Charlotte Behning; Sarah Thiele

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2315.

ARVO Annual Meeting Abstract June 2024

Validating a Confirmatory Structure-Function Model Prognostic of Progression of Intermediate AMD: MACUSTAR Study Primary Endpoint Analysis

Charlotte Behning; Jan Henrik Terheyden; Robert Finger; Hannah M P Dunbar; Marlene Sassmannshausen; Adnan Tufail; David P. Crabb; Alison M Binns; Zhichao Wu; Robyn H Guymer; Nadia Zakaria; Sergio Leal; Steffen Schmitz-Valckenberg; Ulrich F O Luhmann; Matthias Schmid; Frank G Holz

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4314.

ARVO Annual Meeting Abstract June 2024

Prognostic value of structural biomarkers for disease progression in intermediate age-related macular degeneration: a MACUSTAR study report

Marlene Sassmannshausen; Sarah Thiele; Jan Henrik Terheyden; Ulrich F O Luhmann; Sergio Leal; Matthias Schmid; Robert Finger; Frank G Holz; Steffen Schmitz-Valckenberg; Charlotte Behning

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5684.

ARVO Annual Meeting Abstract June 2024

Vision Impairment in Low Luminance Reports and Progression of Intermediate Age-Related Macular Degeneration in the MACUSTAR Study Cohort

Jan Henrik Terheyden; Charlotte Behning; Donna L. Rowen; Jill Carlton; Hannah M P Dunbar; Nadia Zakaria; Sergio Leal; Ulrich F O Luhmann; Matthias Schmid; David P Crabb; Frank G Holz; Robert Finger

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5677.

ARVO Annual Meeting Abstract June 2024

Key baseline disease characteristics in nAMD are not linked to treatment interval extension of aflibercept 8 mg: A post-hoc 96-week PULSAR analysis

Justus G Garweg; Paolo Lanzetta; Varun Chaudhary; Sergio Leal; Tobias Machewitz; xin Zhang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2116.

ARVO Annual Meeting Abstract June 2024

A 96-week PULSAR subgroup analysis: Similar visual and anatomic improvements with aflibercept 8 mg every 12 weeks or longer and 2 mg every 8 weeks, as defined by baseline BCVA, CRT, CNV type, and race

Richard Gale; Oliver Zeitz; Sobha Sivaprasad; Sergio Leal; Tobias Machewitz; xin Zhang

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4906.

ARVO Annual Meeting Abstract June 2024

Improving the detection of progression in longitudinal microperimetry data in age-related macular degeneration by using pointwise analysis of data - a MACUSTAR study report

Jeremy TAN; Giovanni Montesano; Charlotte Behning; Hannah M P Dunbar; Robert Finger; Jan Henrik Terheyden; Stephen H Poor; Sergio Leal; Adnan Tufail; Frank G Holz; Ulrich F O Luhmann; David P. Crabb

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5686.

Retina July 2023

Test-Retest Variability and Discriminatory Power of Measurements From Microperimetry and Dark Adaptation Assessment in People With Intermediate Age-Related Macular Degeneration – A MACUSTAR Study Report

PDF

Bethany E. Higgins; Giovanni Montesano; Hannah M. P. Dunbar; Alison M. Binns; Deanna J. Taylor; Charlotte Behning; Amina Abdirahman; Matthias C. Schmid; Jan H. Terheyden; Nadia Zakaria; Stephen Poor; Robert P. Finger; Sergio Leal; Frank G. Holz; Gary S. Rubin; Ulrich F. O. Luhmann; David P. Crabb; on behalf of the MACUSTAR Consortium
TAGS: age-related macular degeneration, dark adaptation, study report, vision
Trans. Vis. Sci. Tech.. 2023; 12(7):19. https://doi.org/10.1167/tvst.12.7.19

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2023

Subgroup analyses from the Phase 3 PULSAR trial of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration

Sobha Sivaprasad; Sergio Leal; Tobias Machewitz; Xin Zhang

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2238.

ARVO Annual Meeting Abstract June 2023

Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration

Jean-Francois Korobelnik; Ursula Maria Schmidt-Ott; Andrea Schulze; Xin Zhang; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):278.

ARVO Annual Meeting Abstract June 2023

Functional, Anatomical and Patient-Reported Baseline Characteristics of the MACUSTAR Study

Robert Patrick Finger; Jan H. Terheyden; Hannah M P Dunbar; Charlotte Behning; Matthias Schmid; Adnan Tufail; David Crabb; Klaus Peter Moll; Ulrich F O Luhmann; Steffen Schmitz-Valckenberg; Sergio Leal; Frank G Holz

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1751.

ARVO Annual Meeting Abstract June 2023

Intravitreal aflibercept 8 mg in patients with polypoidal choroidal vasculopathy (PCV): A Phase 3 PULSAR trial subgroup analysis

Tien Y Wong; Jeffrey S Heier; Xin Zhang; Tobias Machewitz; Andrea Schulze; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2240.

ARVO Annual Meeting Abstract June 2023

Baseline disease characteristics in patients maintaining q12 and q16 dosing with aflibercept 8 mg versus patients with shortened treatment intervals: A Phase 3 PULSAR post hoc analysis

Paolo Lanzetta; Sergio Leal; Tobias Machewitz; Xin Zhang

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2239.

ARVO Annual Meeting Abstract June 2023

Association of age-related macular degeneration (AMD) retinal biomarkers with AMD polygenic risk scores in the MACUSTAR study cohort

Jan Henrik Terheyden; Charlotte Behning; Marlene Sassmannshausen; sarah thiele; Steffen Schmitz-Valckenberg; Adnan Tufail; Carel C B Hoyng; Matthias Schmid; Ulrich F O Luhmann; Klaus Peter Moll; Sergio Leal; Frank G Holz; Robert P Finger

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2150.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2

Associations between structural phenotype and pathway-specific polygenic risk scores in intermediate age-related macular degeneration – a MACUSTAR report

Comparable efficacy with aflibercept 8 mg at extended dosing intervals beyond q16 versus 2 mg q8 in Asian patients with nAMD in PULSAR through Week 96

Aflibercept 8 mg monotherapy shows maintained efficacy over 96 weeks, with the ability to extend dosing intervals beyond every 16 weeks, in patients with PCV in the PULSAR Phase 3 trial

Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg

The prognostic power of baseline visual function deficits in intermediate age-related macular degeneration (iAMD) for progression to late AMD - A MACUSTAR study report

Association of Ellipsoid Zone Reflectivity and Choriocapillaris Flow in Age-Related Macular Degeneration: a MACUSTAR study report

Validating a Confirmatory Structure-Function Model Prognostic of Progression of Intermediate AMD: MACUSTAR Study Primary Endpoint Analysis

Prognostic value of structural biomarkers for disease progression in intermediate age-related macular degeneration: a MACUSTAR study report

Vision Impairment in Low Luminance Reports and Progression of Intermediate Age-Related Macular Degeneration in the MACUSTAR Study Cohort

Key baseline disease characteristics in nAMD are not linked to treatment interval extension of aflibercept 8 mg: A post-hoc 96-week PULSAR analysis

A 96-week PULSAR subgroup analysis: Similar visual and anatomic improvements with aflibercept 8 mg every 12 weeks or longer and 2 mg every 8 weeks, as defined by baseline BCVA, CRT, CNV type, and race

Improving the detection of progression in longitudinal microperimetry data in age-related macular degeneration by using pointwise analysis of data - a MACUSTAR study report

Test-Retest Variability and Discriminatory Power of Measurements From Microperimetry and Dark Adaptation Assessment in People With Intermediate Age-Related Macular Degeneration – A MACUSTAR Study Report

Subgroup analyses from the Phase 3 PULSAR trial of aflibercept 8 mg in patients with treatment-naïve neovascular age-related macular degeneration

Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration

Functional, Anatomical and Patient-Reported Baseline Characteristics of the MACUSTAR Study

Intravitreal aflibercept 8 mg in patients with polypoidal choroidal vasculopathy (PCV): A Phase 3 PULSAR trial subgroup analysis

Baseline disease characteristics in patients maintaining q12 and q16 dosing with aflibercept 8 mg versus patients with shortened treatment intervals: A Phase 3 PULSAR post hoc analysis

Association of age-related macular degeneration (AMD) retinal biomarkers with AMD polygenic risk scores in the MACUSTAR study cohort

To View More...

You must be signed into an individual account to use this feature.